Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

DISEASE CHARACTERISTICS: Histologically confirmed prostate cancer Disease progression with 3 or more rising PSA levels at least 2 weeks apart with greater than 50% rise above the baseline PSA, despite prostatectomy or radiotherapy Disease progression following primary therapy including surgery or radiotherapy with or without neoadjuvant androgen ablation allowed OR Intermittent hormonal therapy with noncastrate levels of testosterone (greater than 50 ng/mL) allowed No soft tissue and/or bone disease OR No androgen independence without evidence of radiographic disease No change in hormonal therapies (excluding therapies to maintain castrate testosterone levels) including prednisone or dexamethasone within 2 weeks of study No symptomatic or anticipatory (within 6 months) symptomatic disease No active CNS or epidural tumor No radiographic evidence of metastatic disease PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: At least 6 months Hematopoietic: WBC at least 3,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL OR SGOT less than 3 times upper limit of normal Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 40 mL/min Cardiovascular: No New York Heart Association class III or IV heart disease Pulmonary: No severe debilitating pulmonary disease Other: No other active malignancy within the past 5 years except nonmelanoma skin cancer No infection requiring antibiotics No seafood allergies No positive stool guaiac except for hemorrhoids or history of radiotherapy induced proctitis No narcotic dependent pain PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy and recovered At least 8 weeks since prior suramin and/or plasma concentration below 50 microgram/mL Endocrine therapy: See Disease Characteristics Recovered from prior hormonal therapy Concurrent replacement hydrocortisone following prior suramin allowed Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered Surgery: See Disease Characteristics Recovered from prior surgery